(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 51.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Ars Pharmaceuticals's revenue in 2025 is $112,339,000.On average, 5 Wall Street analysts forecast SPRY's revenue for 2025 to be $8,204,364,845, with the lowest SPRY revenue forecast at $7,848,787,685, and the highest SPRY revenue forecast at $8,667,069,755. On average, 5 Wall Street analysts forecast SPRY's revenue for 2026 to be $22,255,493,440, with the lowest SPRY revenue forecast at $15,827,037,871, and the highest SPRY revenue forecast at $25,932,030,829.
In 2027, SPRY is forecast to generate $38,868,892,474 in revenue, with the lowest revenue forecast at $30,548,209,030 and the highest revenue forecast at $46,883,214,273.